MARKET

MGTA

MGTA

Magenta Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.19
-0.43
-3.70%
Opening 13:44 02/27 EST
OPEN
11.43
PREV CLOSE
11.62
HIGH
12.20
LOW
10.83
VOLUME
45.27K
TURNOVER
--
52 WEEK HIGH
21.00
52 WEEK LOW
8.78
MARKET CAP
384.60M
P/E (TTM)
-5.6880
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MGTA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MGTA stock price target is 20.20 with a high estimate of 22.00 and a low estimate of 18.00.

EPS

MGTA News

More
  • Magenta Therapeutics to Participate in Cowen Health Care Conference on Monday, March 2nd in Boston
  • Business Wire · 1d ago
  • Magenta Therapeutics completes patient dosing in early-stage MGTA-145 trial
  • Seeking Alpha - Article · 3d ago
  • Magenta Conditioning Lead Clinical Candidate MGTA-117 Demonstrates Broad Tolerability and High Therapeutic Index in Non-human Primates
  • Business Wire · 3d ago
  • Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial, Demonstrating Rapid, Single-Day First Line Stem Cell Mobilization and Collection
  • Business Wire · 3d ago

Industry

Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
-1.41%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About MGTA

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.
More

Webull offers kinds of Magenta Therapeutics Inc stock information, including NASDAQ:MGTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGTA stock news, and many more online research tools to help you make informed decisions.